|  |
| --- |
| I. **Rheumatology**1. Clinical practice
2. Experimental studies
3. Field

a. Pediatric rheumatic disordersb. Rheumatoid arthritisc. Spondyloarthritisd. Connective tissue diseasese. Osteoarthritisf. Osteoporosisg. Fibromyalgiah. Gout and hyperuricemiai. Lupusj. Lyme diseasek. Vasculitisl. Inflammatory myopathym. Scleroderman. Pain Managemento. Septic arthritis p. Drug induced side effectsq. Supplements in rheumatologic disorders**II. Gastroenterology**1. Clinical practice
2. Experimental studies
3. Field

a. Upper GI disordersb. Lower GI disordersc. Biliary system disordersd. Pancreatic disorderse. GI oncology and polypsf. GI infectious diseaseg. Hepatologyh. Viral hepatitisi. Parenteral nutritionj. Enteral nutritionk. Pediatric gastroenterology l. Obesitym. Transplantationn. Drug induced side effectso. Supplements in gastroenterology/hepatic disordersp. Malabsorption syndrome **III. Nephrology** 1. Acute hyperosmotic milli in kidney medulla by Hypertonic solution and medullary nephrons and interstitial cells function
2. Acute isotonic crystalloid solution and medullary nephrons and interstitial cells function
3. Chronic consumption of sodium and medullary nephrons and interstitial cells function
4. Role of hyperchromic metabolic acidosis
5. Role of chloride ion
6. Role of Macrophage and TH 17 cells
7. Polymorphisms of TonEBP
8. VEGF-C and polymorphisms
9. Glomerulopathy and therapeutic intervention
	1. MicroRNA dysregulation in different population of glomerular cells
		1. Oxidative stress and anti-oxidants
		2. Hyperglycemia and Diabetic drugs
		3. High sodium consumption and Macrophage
	2. Podocytopathy
		1. TRPC5 receptors and therapeutic role of xantin alkaloids
		2. Heparan-binding EG, ADAM and EGFR signaling: therapeutic modalities
10. Drug induced acute and chronic kidney injury and novel mechanism of injury and therapeutic intervention
11. Kidney transplantation
	1. Delayed graft function and kidney graft survival
		1. Ischemic reperfusion injury and therapeutic intervention
		2. Gut microbiota
		3. Clinical study of newer immunosuppressive drug
		4. Pharmacodynamic-pharmacokinetic study of newer immunosuppressive drugs

**IV. Hematology and oncology**1. Branches
	1. Clinical oncology
	2. Experimental oncology
2. Field
	1. Hematologic malignancy
	2. Adverse reaction of chemotherapy regimens
	3. Prevention of infection and other complication in malignant patients
	4. Pain & neuropathic management in malignant patients
	5. Nutritional support in malignant patients
	6. Adjuvant medication for enhance efficacy of chemotherapy

**V. Infectious diseases**1) Clinical practice2) Experimental studiesi. TB management and anti-TB adverse reaction managementii. HIV and related opportunistic infection management iii. CNS infectionsiv. Fever and neutropenia and cancer related infection* + 1. Fungal infections
		2. Viral infection
		3. Endocarditis and vascular infections
		4. Infectious diarrhea
		5. Surgical site infection prevention and management
		6. Skin, bone and soft tissue infection
		7. Abdominal infections
		8. Respiratory tract infections
		9. Brucellosis
		10. Sexually transmitted infections
		11. Urinary tract infection
		12. Viral hepatitis management and prevention
		13. Management of antimicrobial agents adverse reactions
		14. Therapeutic drug monitoring of antimicrobial agents

**VI. Cardiovascular diseases**1) Clinical practice2) Experimental studies1. Dyslipidemia management
2. Hypertension management
3. Coronary artery disease
4. Congenital heart disease
5. Thrombosis
6. Peripheral vascular disease
7. ACS
8. Stable angina
9. Heart failure
10. Cardiac arrhythmia
11. Hypertensive crises
12. DM I and II and their complications

**VII. Pulmonary diseases**1) Clinical practice2) Experimental studies1. Asthma
2. COPD management
3. Acute and chronic rhinitis
4. Cystic fibrosis

**VIII. Psychiatric disorders** 1) Clinical practice2) Experimental studies1. Anxiety disorder
2. Sleep disorder
3. Schizophrenia
4. Depressive disorder
5. Bipolar disorder
6. ADHD
7. Substance abuse
8. Tobacco dependence

**IX. Neurological diseases**1) Clinical practice2) Experimental studies1. MS
2. Headaches
3. Parkinson’s diseases and other movement disorders
4. Seizure
5. Thrombosis
6. Ischemic and hemorrhagic stroke
7. Alzheimer disease

**X. Critical Care Pharmacotherapy**1. Clinical practice
2. Experimental studies
3. Supportive Care
4. Fluid Therapy in the Critically Ill Patient
5. Nutrition Support Therapy in Critically Ill Patients
6. Analgesia
7. Agitation and Comfort in the Intensive Care Unit
8. Delirium in Critically Ill Adults
9. Infectious Diseases
10. Appropriate Use of Antimicrobials
11. Pharmacokinetic and Pharmacodynamic Considerations
12. Laboratory Testing Considerations
13. Antimicrobial Resistance in the Critical Care Environment
14. Severe Sepsis and Septic Shock
15. Antimicrobial Prophylaxis
16. Neurocritical care
17. Traumatic Brain Injury and Acute Spinal Cord Injury
18. Management of Stroke
19. Critical Care Management of Aneurysmal Subarachnoid

Hemorrhage1. Hematology
2. Prevention and Treatment of Venous Thromboembolism
3. Hemostatic Agents for the Prevention and Management of Hemorrhage in the ICU
4. Laboratory Testing with Anticoagulation
5. Acute Kidney Injury
6. Acute Kidney Injury—Prevention and Management
7. Drug Dosing in Acute Kidney Injury and Extracorporeal Therapies
8. Liver/ Gastrointestinal
9. Management and Drug Dosing in Acute Liver Failure
10. Acute Gastrointestinal Bleeding: Prophylaxis and Treatment
11. Acute Pulmonary Disease
12. Pulmonary Arterial Hypertension
13. Critical Care Management of Asthma and Chronic Obstructive Pulmonary Disease
14. Cardiovascular Critical Care
15. Acute Decompensated Heart Failure
16. Management of Acute Coronary Syndrome
17. Management of Cardiac Arrest
18. Pharmacologic Challenges During Mechanical Circulatory Support in Adults
19. Other Urgencies and Emergencies
20. Hypertensive Crisis
21. Medication Withdrawal in the Intensive Care Unit
22. Endocrine Disorders
23. Oncologic Emergencies
24. Miscellaneous
25. Drug Dosing in Special Intensive Care Unit Populations
26. Management of the Critically Ill Burn Patient
27. The Role of Pharmacotherapy in the Treatment of the Multiple Trauma Patient
28. Pediatric Critical Care
29. Drug Interactions in the Intensive Care Unit
30. Acute Illness Scoring Systems
31. Medication Safety and Active Surveillance
32. Clinically Applied Pharmacogenomics in Critical Care Settings

**XI. Clinical Pharmacokinetic studies** **XII. Miscellaneous** 1) Clinical practice2) Experimental studies1. BPH
2. Eye disorders
3. TPN & enteral feeding
4. Pediatric disorders
 |